{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:01:12Z","timestamp":1789984872800,"version":"4.0.1"},"reference-count":63,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Model Rural Health Research Unit (MRHRU), Tripura","award":["Y17016\/1\/2020-21-M2-Comm\/1423"],"award-info":[{"award-number":["Y17016\/1\/2020-21-M2-Comm\/1423"]}]},{"award":["Y17016\/1\/2020-21-M2-Comm\/1423"],"award-info":[{"award-number":["Y17016\/1\/2020-21-M2-Comm\/1423"]}],"id":[{"id":"https:\/\/ror.org\/059qgvg50","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objectives: Adverse drug reactions (ADRs) to antihypertensive medications contribute to poor medication adherence and treatment discontinuation. Pharmacogenomic approaches offer a potential means of identifying genetic variants that predict ADR risks, thereby supporting more tailored antihypertensive therapy and improved tolerability. We systematically identify and synthesize available pharmacogenomic evidence for gene\u2013drug\u2013ADR interaction in hypertension across all major drug classes. Methods: This systematic review follows PRISMA guidelines. Five bibliographic databases were systematically searched for pharmacogenomic studies examining associations between genetic variants and adverse drug reactions in adults receiving antihypertensive therapy. Google Scholar was additionally used as a supplementary source during full-text retrieval and citation screening to identify potentially relevant peer-reviewed publications not captured by the primary database searches. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Newcastle\u2013Ottawa Scale. The protocol was registered in PROSPERO (CRD420251247856). Results: Seven studies published between 2002 and 2024 fulfilled the inclusion criteria, encompassing populations from Pakistan, China, Russia, South Africa, Spain, South Korea, and Japan. Notably, no pharmacogenomic evidence was identified for beta-blockers, angiotensin receptor blockers, thiazide diuretics, alpha-blockers, or loop diuretics when used as antihypertensives. The studies focused on two antihypertensive medication classes: angiotensin-converting enzyme inhibitors (ACE-I) and calcium channel blockers (CCBs). Variants in BDKRB2 have significant links to ACE-I-induced cough in different populations, with individual investigations identifying other genes involved in bradykinin metabolism and signalling (MME, PTGER3) and hepatic drug transport (SLCO1B1). Associations between CCB-related peripheral edema and CYP3A5 polymorphisms were found in Chinese Han and Russian Caucasian groups. The quality of the studies varied, but two were rated as good. Conclusions: Preliminary pharmacogenomic evidence linking antihypertensive medications to ADRs is emerging but remains limited in scope and concentrated in two drug classes. These findings represent early-phase, hypothesis-generating contributions to the evidence base required for personalized medicine in hypertension pharmacotherapy. Realizing this potential will require prospective validation in diverse, multi-ethnic cohorts, standardization of ADR reporting and causality assessment, and sustained investment in pharmacogenomic implementation science.<\/jats:p>","DOI":"10.3390\/ph19091488","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:38Z","timestamp":1789981298000},"page":"1488","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping Pharmacogenomic Determinants of Adverse Drug Reactions in Hypertension: A Systematic Review"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-5228","authenticated-orcid":false,"given":"Viola Savy","family":"Dsouza","sequence":"first","affiliation":[{"name":"NIMS Institute of Public Health and Governance, NIMS University Rajasthan, Jaipur 303121, India"},{"name":"Former Model Rural Health Research Unit Tripura, Agartala 799045, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jestina Rachel","family":"Kurian","sequence":"additional","affiliation":[{"name":"Department of Applied Statistics and Data Science, Prasanna School of Public Health, Manipal Academy of Higher Education (MAHE), Manipal 576104, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1257-2618","authenticated-orcid":false,"given":"Manoj","family":"Kalita","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Health Research (ICMR NIHR), Dibrugarh 786010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaustubh","family":"Bora","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Health Research (ICMR NIHR), Dibrugarh 786010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Phukan","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Health Research (ICMR NIHR), Dibrugarh 786010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Agartala Government Medical College, Agartala 799006, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-4762","authenticated-orcid":false,"given":"Ipsita Pal","family":"Bhowmick","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Health Research (ICMR NIHR), Dibrugarh 786010, India"},{"name":"Model Rural Health Research Unit Tripura, Agartala 799045, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/HJH.0000000000003563","article-title":"Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension","volume":"42","author":"Charchar","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_2","unstructured":"CDC (2026, May 04). High Blood Pressure Risk Factors, Available online: https:\/\/www.cdc.gov\/high-blood-pressure\/risk-factors\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","article-title":"Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants","volume":"389","author":"Zhou","year":"2017","journal-title":"Lancet"},{"key":"ref_4","unstructured":"World Health Organisation, London IC (2026, May 04). More than 700 Million People with Untreated Hypertension. Available online: https:\/\/www.who.int\/news\/item\/25-08-2021-more-than-700-million-people-with-untreated-hypertension."},{"key":"ref_5","unstructured":"Ostchega, Y., Fryar, C.D., Nwankwo, T., and Nguyen, D.T. (2026, May 04). Hypertension Prevalence Among Adults Aged 18 and over: United States, 2017\u20132018, Available online: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db364.html."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"He, C., Lu, S., Yu, H., Sun, Y., and Zhang, X. (2025). Global, regional, and national disease burden attributable to high systolic blood pressure in youth and young adults: 2021 Global Burden of Disease Study analysis. BMC Med., 23.","DOI":"10.1186\/s12916-025-03918-1"},{"key":"ref_7","unstructured":"GM Insights (2026, May 04). Antihypertensive Drugs Market Size, Statistics Report 2034. Available online: https:\/\/www.gminsights.com\/industry-analysis\/antihypertensive-drugs-market."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/HJH.0000000000002056","article-title":"Determinants of the high admission blood pressure in mild-to-moderate acute intracerebral hemorrhage","volume":"37","author":"Wang","year":"2019","journal-title":"J. Hypertens."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lee, F.Y., Islahudin, F., Gafor, A.H.A., Wong, H.-S., Bavanandan, S., Saffian, S.M., Redzuan, A.M., and Makmor-Bakry, M. (2022). Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.848804"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00007611-198405000-00020","article-title":"Antihypertensive Medications","volume":"77","author":"Oster","year":"2023","journal-title":"South. Med. J."},{"key":"ref_11","unstructured":"Singh, B., Cusick, A.S., Goyal, A., and Patel, P. (2026, May 04). ACE Inhibitors, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430896\/."},{"key":"ref_12","unstructured":"Patel, P., and Launico, M.V. (2026, May 04). Angiotensin II Receptor Blockers (ARB), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537027\/."},{"key":"ref_13","unstructured":"McKeever, R.G., Patel, P., and Hamilton, R.J. (2026, May 04). Calcium Channel Blockers, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482473\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","article-title":"Thiazide and loop diuretics","volume":"13","author":"Sica","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_15","unstructured":"Celi, I., and Bet, B. (2025, December 24). Cardiology Advisor. Available online: https:\/\/www.thecardiologyadvisor.com\/ddi\/beta-blockers\/#:~:text=%CE%B2%2Dadrenergic%20receptor%20(AR),1."},{"key":"ref_16","unstructured":"Nachawati, D., Leslie, S.W., and Patel, J.B. (2026, May 04). Alpha-Blockers, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556066\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm. J. SPJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e026582","DOI":"10.1161\/JAHA.122.026582","article-title":"Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients","volume":"11","author":"Lee","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.51866\/oa.651","article-title":"Association between medication adherence and blood pressure control and factors associated with antihypertensive medication adherence in the Melaka Tengah District: A cross-sectional survey","volume":"19","author":"Suleiman","year":"2024","journal-title":"Malays. Fam. Physician"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11096-024-01832-9","article-title":"Exploring the association of adverse drug reactions with medication adherence and quality of life among hypertensive patients: A cross-sectional study","volume":"47","author":"Insani","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40885-018-0104-6","article-title":"Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital","volume":"25","author":"Gebreyohannes","year":"2019","journal-title":"Clin. Hypertens."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Soria-Chacartegui, P., Zubiaur, P., Ochoa, D., Villapalos-Garc\u00eda, G., Rom\u00e1n, M., Matas, M., Figueiredo-Tor, L., Mej\u00eda-Abril, G., Calleja, S., and de Miguel, A. (2023). Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020404"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.mayocp.2017.09.001","article-title":"Pharmacogenomics: Precision Medicine and Drug Response","volume":"92","author":"Weinshilboum","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41525-019-0111-x","article-title":"Evaluating the promise of inclusion of African ancestry populations in genomics","volume":"5","author":"Bentley","year":"2020","journal-title":"npj Genom. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9919677","DOI":"10.1155\/2023\/9919677","article-title":"Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic-Based Approach for the Treatment of Hypertension in Africans","volume":"2023","author":"Katsukunya","year":"2023","journal-title":"Int. J. Hypertens."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/GIM.0b013e3181ca2bbf","article-title":"Impact of limited population diversity of genome-wide association studies","volume":"12","author":"Haga","year":"2010","journal-title":"Genet. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/HYPERTENSIONAHA.107.104273","article-title":"Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic","volume":"52","author":"Turner","year":"2008","journal-title":"Hypertension"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1474-4422(08)70241-2","article-title":"Genome-wide association studies in neurological disorders","volume":"7","author":"Singleton","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpt.709","article-title":"Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing","volume":"102","author":"Wadhwa","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","first-page":"341","article-title":"Pharmacogenomics and Hypertension: Current Insights","volume":"12","author":"Pereira","year":"2019","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40246-024-00648-y","article-title":"A qualitative approach to assess the opinion of physicians about the challenges and prospects of pharmacogenomic testing implementation in clinical practice in Greece","volume":"18","author":"Koufaki","year":"2024","journal-title":"Hum. Genom."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hippman, C., and Nislow, C. (2019). Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. J. Pers. Med., 9.","DOI":"10.3390\/jpm9030040"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41397-024-00326-1","article-title":"A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: A reality for future health care","volume":"24","author":"Chenchula","year":"2024","journal-title":"Pharmacogenom. J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bellanca, C.M., Augello, E., Cantone, A.F., Di Mauro, R., Attaguile, G.A., Di Giovanni, V., Condorelli, G.A., Di Benedetto, G., Cantarella, G., and Bernardini, R. (2023). Insight into Risk Factors, Pharmacogenetics\/Genomics, and Management of Adverse Drug Reactions in Elderly: A Narrative Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16111542"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/jch.14653","article-title":"Comprehensive effects of lifestyle reform, adherence, and related factors on hypertension control: A review","volume":"25","author":"Ojangba","year":"2023","journal-title":"J. Clin. Hypertens."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ostaiza-Cardenas, J., Tobar, A.C., Costa, S.C., Calero, D.S., L\u00f3pez-Carrera, A., Berm\u00fadez, F.G., and Orellana-Manzano, A. (2025). Epigenetic modulation by life-style: Advances in diet, exercise, and mindfulness for disease prevention and health optimization. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1632999"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12955-018-0921-z","article-title":"Relationships among medication adherence, lifestyle modification, and health-related quality of life in patients with acute myocardial infarction: A cross-sectional study","volume":"16","author":"Lee","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Das, S., Kalita, M., Makhal, M., Devaraja, M., Bagepally, B.S., Cherian, J.J., Aadityan, R., Bhattacharjee, M., Mondal, S., and Sen, S. (2024). Pharmacogenomics-assisted treatment versus standard of care in schizophrenia: A systematic review and meta-analysis. BMC Psychiatry, 24.","DOI":"10.1186\/s12888-024-06104-4"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.sapharm.2025.02.008","article-title":"Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients","volume":"21","author":"Dsouza","year":"2025","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin. Med."},{"key":"ref_43","unstructured":"Wells, G., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2025, December 24). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in Meta-Analyses. Available online: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale#:~:text=It%20was%20developed%20to%20assess,the%20interpretation%20of%20meta%2Danalytic%20results."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/FPC.0b013e328341041c","article-title":"Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough","volume":"21","author":"Grilo","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/sj.jhh.1001486","article-title":"Association of polymorphisms of the renin\u2013angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough","volume":"16","author":"Mukae","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2710.2009.01028.x","article-title":"Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans","volume":"34","author":"Woo","year":"2009","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jch.12104","article-title":"Association of B2 Receptor Polymorphisms and ACE Activity with ACE Inhibitor\u2013Induced Angioedema in Black and Mixed-Race South Africans","volume":"15","author":"Moholisa","year":"2013","journal-title":"J. Clin. Hypertens."},{"key":"ref_48","first-page":"435","article-title":"Approaches to predicting the efficacy and safety of amlodipine in patients with arterial hypertension of I\u2013II degree based on pharmacogenetic studies","volume":"14","author":"Sychev","year":"2019","journal-title":"Med. News North Cauc."},{"key":"ref_49","first-page":"189","article-title":"Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension","volume":"14","author":"Liang","year":"2021","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Sheikh, A.F., Munawar, N., Nawaz, R., Khan, H., Rafique, M., Jahan, F., and Ahmed, S. (2024). Association of SLCO1B1 gene variants with angiotensin-converting enzyme inhibitor-induced cough in a Pakistani hypertensive cohort. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1441251"},{"key":"ref_51","unstructured":"Khalil, H., and Zeltser, R. (2026, May 04). Antihypertensive Medications, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554579\/."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","article-title":"Peripheral edema associated with calcium channel blockers: Incidence and withdrawal rate\u2014A meta-analysis of randomized trials","volume":"29","author":"Makani","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/ph3061779","article-title":"The Pharmacogenomics of Anti-Hypertensive Therapy","volume":"3","author":"Padmanabhan","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_54","unstructured":"Herman, L.L., Padala, S.A., Ahmed, I., and Bashir, K. (2026, May 04). Angiotensin-Converting Enzyme Inhibitors (ACEI), Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/28613705\/."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrneph.2015.176","article-title":"Hypertension pharmacogenomics: In search of personalized treatment approaches","volume":"12","author":"Johnson","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.4103\/jfmpc.jfmpc_831_21","article-title":"Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions","volume":"10","author":"Shukla","year":"2021","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.HYP.36.1.127","article-title":"Bradykinin B2 Receptor Gene Polymorphism Is Associated with Angiotensin-Converting Enzyme Inhibitor\u2013Related Cough","volume":"36","author":"Mukae","year":"2000","journal-title":"Hypertension"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1053\/meta.2001.27212","article-title":"Angiotensin-converting enzyme gene insertion\/deletion, not bradykinin B2 receptor-58T\/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non [ndash] insulin-dependent diabetes mellitus","volume":"50","author":"Lee","year":"2001","journal-title":"Metabolism"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhang, G., Liu, J., Wang, Z., Zou, L., and Ding, Y. (2024). Global Research Status and Trends in Pharmacogenomics: Bibliometric Analysis and Visualization of the Past 20 Years. Preprint.","DOI":"10.2139\/ssrn.4745871"},{"key":"ref_60","unstructured":"World Health Organization (2025, December 26). Hypertension. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension#:~:text=Key%20facts,%25)%20have%20it%20under%20control."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCRESAHA.120.318729","article-title":"Hypertension in Low- and Middle-Income Countries","volume":"128","author":"Schutte","year":"2021","journal-title":"Circ. Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Prabha, C., Bera, O.P., Mantri, N., Kaushal, R., Goel, A.D., Gupta, M.K., Charan, J., Joshi, N., and Bhardwaj, P. (2025). National prevalence and regional variation in the burden of hypertension in India: A systematic review and meta-analysis. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-24766-x"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron , I., Hoffmann , T.C., Mulrow , C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372.","DOI":"10.1136\/bmj.n71"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1488\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:09:08Z","timestamp":1789981748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091488"],"URL":"https:\/\/doi.org\/10.3390\/ph19091488","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}